Application of QbD based approach in development and validation of RP‐HPLC method for simultaneous estimation of methotrexate and baicalin in dual‐drug‐loaded liposomes

Abstract

AbstractThe present study delineates the development of a novel, rugged and sensitive stability‐indicating risk‐based HPLC method for the concurrent estimation of methotrexate (MTX) and baicalin (BCL) in dual‐drug‐loaded‐nanopharmaceuticals based on an analytical quality‐by‐design approach. Preliminary screening trials along with systemic risk analysis were performed, endeavouring to explicate the critical method attributes, namely pH, percentage of orthophosphoric acid and percentage of acetonitrile, that influence the critical quality attributes. Box–Behnken design was utilized for the optimization of the tailing factor as the response for MTX and BCL in a short run time. The chromatographic conditions were optimized by performing 17 experimental runs using design expert software. The chromatographic conditions were selected after the analysis of the optimized zone within the confines of the design space: water:acetonitrile adjusted to a pH of 3.0 with 0.05% orthophosphoric acid (60:40, %v/v) was the mobile phase, the flow rate was 1.0 ml/min and an analytical C18 column was used at an isobestic wavelength of 282 nm. Furthermore, the optimized method was validated in accordance with the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines and was found to be within the prescribed limits. Therefore, the developed reversed‐phase‐high‐performance liquid chromatography method has a high degree of practical utility for synchronous detection of MTX and BCL in pharmaceutical nano‐dosage forms such as protein‐based nanoparticles, nanocrystals, polymeric nanoparticles and metallic nanoparticles in in vivo and in vitro studies.